Compile Data Set for Download or QSAR
Report error Found 355 Enz. Inhib. hit(s) with all data for entry = 9220
TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398106(US10323000, Compound 41 | Preparations of 4-chloro...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398233(US10323000, Compound 173 | 4-chloro-N-((4,4-difluo...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398147(US10323000, Compound 83 | 4-chloro-N-((1-hydroxy-3...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM450521(US10676433, Compound 153)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398085(US10323000, Compound 21 | (R)-4-chloro-N-((3,3-dif...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398146(US10323000, Compound 82 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398263(US10323000, Compound 208 | 4-Chloro-1-dimethylcarb...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398261(US10323000, Compound 205 | 4-Chloro-1-dimethylcarb...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398259(US10323000, Compound 200 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398141(US10323000, Compound 75 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398157(US10323000, Compound 93 | 4-chloro-N-(((1R,3R)-1-h...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM450530(US10676433, Compound 163)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398117(US10323000, Compound 51 | 4-chloro-1-(oxetan-3-yl)...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398154(US10323000, Compound 90 | Preparations of 4-chloro...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398073(US10323000, Compound 9 | 4-Chloro-1-(3,3-difluoro-...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398134(US10323000, Compound 68 | 4-chloro-1-(oxetan-3-yl)...)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM450448(US10676433, Compound 76 | US10676433, Compound 158)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM450448(US10676433, Compound 76 | US10676433, Compound 158)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398219(US10323000, Compound 157 | 4-chloro-N-((3,3-difluo...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398071(US10323000, Compound 7 | US10676433, Compound 7)
Affinity DataIC50: 10nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398218(US10323000, Compound 156 | 4-chloro-N-((3,3-difluo...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398233(US10323000, Compound 173 | 4-chloro-N-((4,4-difluo...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398217(US10323000, Compound 155 | 4-chloro-N-((3, 3-diflu...)
Affinity DataIC50: 10nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398130(US10323000, Compound 64 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398130(US10323000, Compound 64 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398128(US10323000, Compound 62 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398128(US10323000, Compound 62 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398263(US10323000, Compound 208 | 4-Chloro-1-dimethylcarb...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398125(US10323000, Compound 59 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398262(US10323000, Compound 207 | 4-Chloro-1-diethylcarba...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398125(US10323000, Compound 59 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398261(US10323000, Compound 205 | 4-Chloro-1-dimethylcarb...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398260(US10323000, Compound 203 | 4-Chloro-1-[(isopropyl-...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398124(US10323000, Compound 58 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398122(US10323000, Compound 56 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398259(US10323000, Compound 200 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398136(US10323000, Compound 70 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398135(US10323000, Compound 69 | 4-chloro-N-((3, 3-difluo...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398134(US10323000, Compound 68 | 4-chloro-1-(oxetan-3-yl)...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398133(US10323000, Compound 67 | 4-chloro-N—(((S)-3,...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398133(US10323000, Compound 67 | 4-chloro-N—(((S)-3,...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398132(US10323000, Compound 66 | 4-chloro-N—(((R)-3,...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398131(US10323000, Compound 65 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398147(US10323000, Compound 83 | 4-chloro-N-((1-hydroxy-3...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398141(US10323000, Compound 75 | 4-Chloro-1-oxetan-3-yl-1...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398156(US10323000, Compound 92 | 4-chloro-N-((4,4-difluor...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398155(US10323000, Compound 91 | 4-chloro-N-((3,3-difluor...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398154(US10323000, Compound 90 | Preparations of 4-chloro...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398150(US10323000, Compound 86 | 4-chloro-N-((3,3-difluor...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398150(US10323000, Compound 86 | 4-chloro-N-((3,3-difluor...)
Affinity DataIC50: 55nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

Displayed 1 to 50 (of 355 total ) | Next | Last >>
Jump to: